Novel Lactobacillus Strains And Their Use Against Helicobacter Pylori

Abstract

The invention concerns new isolated Lactobacillus cells, which are capable of aggregating Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.

1 . Isolated  Lactobacillus  cells, which are capable of aggregating  Helicobacter pylori  under culture conditions of the human digestive tract, in particular of the stomach. 
     
     
         2 . Isolated  Lactobacillus  cells according to  claim 1  and as filed under DSM 17646, DSM 17647, DSM 17648, DSM 17649, DSM 17650, DSM 17651, DSM 17652 or DSM 17653. 
     
     
         3 . A pharmaceutical composition and/or dietetic composition comprising a physiologically effective dose of  Lactobacillus  cells according to  claim 1  or  2  and a physiologically tolerated carrier. 
     
     
         4 . The use of  Lactobacillus  cells according to  claim 1  or  2  for the production of a pharmaceutical or dietetic composition. 
     
     
         5 . The use of  Lactobacillus  cells according to  claim 1  or  2  for the production of a pharmaceutical or dietetic composition for the prophylaxis and/or treatment of diseases caused by infection with  Helicobacter pylori,  in particular gastrointestinal diseases, such as stomach ulcer. 
     
     
         6 . The pharmaceutical composition or the use according to one of  claims 3  to  5 , wherein the composition contains 10̂2 to 10̂15, preferably 10̂6 or 10̂8 to 10̂12, in particular 10̂8 to 10̂10,  Lactobacillus  cells. 
     
     
         7 . The pharmaceutical composition or the use according to one of  claims 3  to  6 , wherein the composition is prepared for oral administration. 
     
     
         8 . The pharmaceutical composition or the use according to one of  claims 3  to  7 , wherein the  Lactobacillus  cells are lyophilized. 
     
     
         9 . The pharmaceutical composition or the use according to one of  claims 3  to  8 , wherein the carrier is selected from the group comprising “maltodextrin, microcrystalline cellulose, starch, in particular corn starch, levulose, lactose, dextrose, and mixtures of such substances”. 
     
     
         10 . The pharmaceutical composition or the use according to one of  claims 3  to  9 , wherein the composition contains 0.1 to 95% by weight carrier and 5 to 99.9% by weight lyophilized  Lactobacillus  cells. 
     
     
         11 . The dietetic composition or the use according to one of  claims 3  to  5 , wherein the composition contains 10̂2 to 10̂15, preferably 10̂6 to 10̂9, in particular 10̂7 to 10̂9,  Lactobacillus  cells. 
     
     
         12 . The dietetic composition or the use according to one of  claim 3  to  5  or  11 , wherein the physiologically tolerated carrier is a food material, in particular selected from the group comprising “milk products, fermented milk products, milk, yogurt, cheese, cereals, muesli bars, and children's food preparations”. 
     
     
         13 . A method for producing a pharmaceutical and/or dietetic composition according to  claims 3  to  12 , wherein a physiologically effective quantity of the lyophilized or non-lyophilized  Lactobacillus  cells is mixed with the physiologically tolerated carrier and prepared for oral administration. 
     
     
         14 . A method for the prophylaxis and/or treatment of a person who suffers from a disease caused by a  Helicobacter pylori  infection or is suspected to fall ill with such a disease, wherein the person is administered a physiologically effective dose of a pharmaceutical and/or dietetic composition according to  claims 3  to  12  one to five times per day.